Developing Vaccine Therapies Addressing Notable Unmet Needs in Lung Cancer
OSE Immunotherapeutics Key Opinion Leader Webinar
The event will feature Dr Stephen Liu, medical oncologist, Georgetown University (Washington DC, United States), who will discuss the unmet medical need and therapeutic landscape in lung cancer.
Professor Benjamin Besse, medical oncologist, director of clinical research at the Gustave Roussy Institute (Villejuif, France), will present the Artemia study, the registration Phase III clinical trial of Tedopi® in non-small cell lung cancer.
Soo Romanoff, managing director of healthcare at Edison Group, will chair the panel and Q&A.
About OSE Immunotherapeutics
OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immune-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi®, a revolutionary cancer vaccine that has recently demonstrated promising outcomes in a Phase III study involving non-small cell lung cancer patients facing secondary resistance following checkpoint inhibitor treatment. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.
Over the past fifteen years, he has authored more than 50 peer-reviewed international scientific publications and holds over 40 issued patents in the field of immunotherapy. Nicolas Poirier and his team have obtained more than 45 million euros in French and European public funding to co-finance OSE Immunotherapeutics’ research and development programs.
